ID

42084

Beskrivning

Study ID: 110921 Clinical Study ID: 110921 Study Title: A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00811733 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT00811733 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Ofatumumab Trade Name: N/A Study Indication: Waldenstrom Macroglobulinaemia The primary objective of this open-label, multi-center, Phase II study was to evaluate the safety and efficacy of Ofatumumab in subjects diagnosed with Waldenstrom Macroglobulinaemia. For the study, eligible subjects were enrolled to receive up to 3 cycles of treatment with Ofatumumab. The first cycle consisted of a single dose of 300 mg followed by 3 weekly doses of 1000 mg (Treatment Group A) or 4 weekly doses of 2000 mg (Treatment Group B) of Ofatumumab, with response assessment beginning at Week 12. Based on the Week 12-16 response, eligible subjects could receive up to 2 additional cycles of treatment. This form has to be filled out at the end of study/ end of treatment. Complete this Form when the subject permanently stops the investigational product (IP). If the subject decided to withdraw consent and stop participation in the study, also complete the End of Study Form. If the subject decided to permanently stop the investigational product but will be followed for disease progression or survival per protocol, do not complete the End of Study Form until follow-up is complete.

Länk

https://clinicaltrials.gov/ct2/show/NCT00811733

Nyckelord

  1. 2021-03-30 2021-03-30 -
Rättsinnehavare

GlaxoSmithKline

Uppladdad den

30 mars 2021

DOI

För en begäran logga in.

Licens

Creative Commons BY-NC 4.0

Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

GSK Ofatumumab in Waldenstrom Macroglobulinaemia, NCT00811733

Investigational product discontinuation

Administrative Data
Beskrivning

Administrative Data

Alias
UMLS CUI-1
C1320722
date of visit/assessment
Beskrivning

date of visit/assessment

Datatyp

date

Alias
UMLS CUI [1]
C1320303
UMLS CUI [2]
C2985720
subject number
Beskrivning

subject ID

Datatyp

text

Alias
UMLS CUI [1]
C2348585
Investigational Product Discontinuation
Beskrivning

Investigational Product Discontinuation

Alias
UMLS CUI-1
C0304229
UMLS CUI-2
C0457454
Give primary reason Investigational Product was permanently stopped
Beskrivning

Select "Adverse event", if the subject has an adverse event due to any cause other than disease progression and the investigational product is permanently stopped due to the adverse event or if the subject died due to any cause other than disease progression. Record details on the Non-Serious Adverse Events or Serious Adverse Events forms as appropriate. Select "investigator discretion" only if the subject permanently stops the IP at the investigator's discretion and none of the other primary reasons apply. Select "Decision by subject or proxy" only if the subject decided to permanently stop the IP and none of the other primary reasons apply.

Datatyp

integer

Alias
UMLS CUI [1,1]
C0304229
UMLS CUI [1,2]
C0457454
UMLS CUI [1,3]
C1549995
If investigator discretion, please specify:
Beskrivning

Investigational product discontinuation, specification investigator discretion

Datatyp

text

Alias
UMLS CUI [1,1]
C0304229
UMLS CUI [1,2]
C0457454
UMLS CUI [1,3]
C0008961
UMLS CUI [1,4]
C0022423
If decision by subject or proxy, please specify:
Beskrivning

Investigational product discontinuation, specification decision by subject or proxy

Datatyp

text

Alias
UMLS CUI [1,1]
C0304229
UMLS CUI [1,2]
C0457454
UMLS CUI [1,3]
C0679006
UMLS CUI [1,4]
C0681850
UMLS CUI [2,1]
C0304229
UMLS CUI [2,2]
C0457454
UMLS CUI [2,3]
C0679006
UMLS CUI [2,4]
C0600420

Similar models

Investigational product discontinuation

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Administrative Data
C1320722 (UMLS CUI-1)
date of visit/assessment
Item
date of visit/assessment
date
C1320303 (UMLS CUI [1])
C2985720 (UMLS CUI [2])
subject ID
Item
subject number
text
C2348585 (UMLS CUI [1])
Item Group
Investigational Product Discontinuation
C0304229 (UMLS CUI-1)
C0457454 (UMLS CUI-2)
Item
Give primary reason Investigational Product was permanently stopped
integer
C0304229 (UMLS CUI [1,1])
C0457454 (UMLS CUI [1,2])
C1549995 (UMLS CUI [1,3])
Code List
Give primary reason Investigational Product was permanently stopped
CL Item
disease progression (including death due to disease progression) (91)
CL Item
completed scheduled treatment (92)
CL Item
adverse event (1)
CL Item
protocol deviation (3)
CL Item
study closed/terminated  (5)
CL Item
lost to follow-up (6)
CL Item
investigator discretion (7)
CL Item
Decision by subject or proxy (8)
Investigational product discontinuation, specification investigator discretion
Item
If investigator discretion, please specify:
text
C0304229 (UMLS CUI [1,1])
C0457454 (UMLS CUI [1,2])
C0008961 (UMLS CUI [1,3])
C0022423 (UMLS CUI [1,4])
Investigational product discontinuation, specification decision by subject or proxy
Item
If decision by subject or proxy, please specify:
text
C0304229 (UMLS CUI [1,1])
C0457454 (UMLS CUI [1,2])
C0679006 (UMLS CUI [1,3])
C0681850 (UMLS CUI [1,4])
C0304229 (UMLS CUI [2,1])
C0457454 (UMLS CUI [2,2])
C0679006 (UMLS CUI [2,3])
C0600420 (UMLS CUI [2,4])

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial